Atorvastatin

ATORVASTATIN CA · Atorvastatin (Subject to Patent free) · ATORVASTATIN CALCIUM SALT · Atorvastatin acid · ATORVASTATIN DIPROTECTED · Atorvastatin CalciuM Tablets · (3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid · Cardyl

https://huagongshe.com/de/chemical/60823

Identifikatoren & physikalische Daten

CAS No.	134523-00-5
Summenformel	C33H35FN2O5
Durchschnittliche Molmasse	558,6 g/mol
Monoisotopische Masse	558,25300038 g/mol
SMILES	CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
InChIKey	XUKUURHRXDUEBC-KAYWLYCHSA-N
PubChem CID	60823
ChEMBL	CHEMBL1487
ChEBI	CHEBI:39548
EC No.	806-698-0
DTXSID	DTXSID8029868

Chemische & physikalische Eigenschaften

XLogP	5
Polarare Oberfläche (TPSA)	112
H-Brücken-Donoren	4
H-Brücken-Akzeptoren	6
Frei drehbare Bindungen	12
Schwere Atome	41
Formalladung	0
Komplexität	822
LogP (Verteilungskoeffizient)	6.36
Löslichkeit	Practically insolubleDMSO: 100 mg/mL (179.01 mM)
Siedepunkt	722722.2±60.0 °C(Predicted)
Schmelzpunkt	176159.1 - 190.6 °C176-178°C
Optical Rotation	White to off-white crystalline powder. Specific optical rotation at 25 °C for D (sodium) line = -7.4 deg (c = 1 in DMSO). Freely soluble in methanolslightly soluble in ethanolvery slightly soluble in acetonitrile, distilled water, phosphate buffer (pH 7.4). Insoluble in aqueous solutions of pH 4 and below. /Atorvastatin calcium salt trihydrate/
Physical Description	Solid
Stability/Shelf Life	Stable under recommended storage conditions. /Atorvastatin calcium salt trihydrate/
Dissociation Constants	4.464.54
Collision Cross Section	224.3 Å² [M]+ [CCS Type: DTBuffer gas: N2Ionization: APCI+Dataset: TOXCASTSource Identifier: DTXSID6044303]231.4 Å² [M+Na]+ [CCS Type: DTIonization: ESI+Source Identifier: DTXSID8029868]229.7 Å² [M+H]+ [CCS Type: DT232.2 Å² [M+Na]+ [CCS Type: DT229.1 Å² [M+H]+ [CCS Type: DT228.4 Å² [M-H]- [CCS Type: DTIonization: ESI-228.6 Å² [M-H]- [CCS Type: DT229.8 Å² [M+H]+ [CCS Type: DT230.3 Å² [M+H]+ [CCS Type: DT213.25 Å² [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]229.87 Å² [M+Na]+ [CCS Type: TW231.37 Å² [M+K]+ [CCS Type: TW231.29 Å² [M+H]+ [CCS Type: TW233 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]233.34 Å² [M+H]+231.92 Å² [M-H]-233.2 Å² [M+Na]+
Other Experimental Properties	pKa= 4.46. Solubility in water (30 °C) = 20.4 ug/mL (pH 2.1)1.23 mg/mL (pH 6.0) /Atorvastatin sodium salt/MP: 159.2-160.7 °C. Specific optical rotation: +26.05 deg at 25 °C/D (c = 1 in chloroform) /Atorvastatin lactone/
Dichte	1.23±0.1 g/cm3(Predicted)
Lagerbedingungen	2-8°C
Aggregatzustand	Solid
pKa (Säurekonstante)	pKa 4.46(H2O t=30 Iuncontrolled) (Uncertain)
Farbe	White to light yellow
Hauptanwendungen	pharmaceutical
InChIKey	XUKUURHRXDUEBC-FQWVHLSFNA-N
SMILES	C(C1=C(N(CC[C@@H](O)C[C@@H](O)CC(=O)O)C(C2C=CC(F)=CC=2)=C1C1C=CC=CC=1)C(C)C)(=O)NC1C=CC=CC=1 \|&1:6,9,r\|
CAS Datenbank	134523-00-5(CAS DataBase Reference)
EPA chemische Informationen	1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, (?R,?R)- (134523-00-5)

Sicherheit & Vorschriften

GHS-Einstufung	WarningH315 (66.7%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (66.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (66.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]H361f (33.3%): Suspected of damaging fertility [Warning Reproductive toxicity]H361fd (33.3%): Suspected of damaging fertilitySuspected of damaging the unborn child [Warning Reproductive toxicity]H362 (66.7%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]P203, P260, P261, P263, P264, P264+P265, P270, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
FDA-Anforderungen	The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including atorvastatin calcium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Atorvastatin calcium/
Toxic Combustion Products	Special hazards arising from the substance or mixture: Carbon oxides, nitrogen oxides (NOx), hydrogen fluoride, calcium oxide /Atorvastatin calcium salt trihydrate/
Hazard Classes and Categories	Skin Irrit. 2 (66.7%)Eye Irrit. 2 (66.7%)STOT SE 3 (66.7%)Repr. 2 (33.3%)Lact. (66.7%)

Anwendungen & Verwendung

History

Parke-Davis's Lipitor (Atorvastatin) was discovered in the mid- to late 1980s and brought to market in 1997. Already ahead of it were four statins: Merck's Mevacor and Zocor, Bristol-Myers Squibb's Pravachol, and Sandoz's Lescol. Despite the competition, by 2006 Lipitor had become the best-selling drug in history, with one-year sales totaling $12.9 billion, more than the net worth of the 10th biggest drug company in the world.

Verwenden

antihyperlipoproteimic;HMG-CoA reductase inhibition